Early biochemical indicators of the obliterative bronchiolitis syndrome in lung transplantation.
The diagnosis of the obliterative bronchiolitis syndrome in lung transplantation is presently best established by evaluation of postoperative lung function tests. Unfortunately the decline in lung function occurs only when obliteration has progressed significantly and is therefore not an early predictive indicator. To distinguish patients at increased risk for the development of obliterative bronchiolitis, we regularly assessed the chemiluminescence response of polymorphonuclear leukocytes, opsonic capacity, and plasma elastase/beta-N-acetylglucosaminidase in 52 outpatients (25 women and 27 men; mean age 45 +/- 12 years) who underwent transplantation between January 1991 and January 1992. Recent onset bronchiolitis within the described observation period occurred in 16 patients (group obliterative bronchiolitis). A matched cohort of 16 patients was formed according to type of procedure, age and follow-up (control) from the remaining 36 patients. Data obtained from a period 6 months before clinical onset of the syndrome showed a significant drop of the opsonic capacity (group obliterative bronchiolitis = 87% +/- 7%; control = 100% +/- 9%; p < 0.023) and rise of the N-acetyl-D-glucosaminidase (group obliterative bronchiolitis = 7.5 +/- 2 U/L; control = 5.8 +/- 1.8 U/L; p < 0.04). No correlation was found between the number of infectious events or rejection episodes and the incidence of obliterative bronchiolitis. According to these results, it can be concluded that a decrease in the plasma opsonic capacity and a rise in beta-N-acetylglucosaminidase may be early markers before clinical onset of obliterative bronchiolitis. The nonspecific immune system may therefore play an important role in the development of obliterative bronchiolitis.
Hausen
B
B
Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Germany.
Dwenger
A
A
Gohrbandt
B
B
Niedermeyer
J
J
Zink
C
C
Demertzis
S
S
Schäfers
H J
HJ
D000118:Acetylglucosaminidase / Q000097:blood; D001989:Bronchiolitis Obliterans / Q000097:blood / Q000175:diagnosis*; D005260:Female; D006084:Graft Rejection / Q000175:diagnosis; D006801:Humans; D007958:Leukocyte Count; D008163:Luminescent Measurements; D008165:Luminol / Q000494:pharmacology; D016040:Lung Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism; D009894:Opportunistic Infections / Q000175:diagnosis; D009895:Opsonin Proteins / Q000097:blood; D010196:Pancreatic Elastase / Q000097:blood; D018410:Pneumonia, Bacterial / Q000175:diagnosis; D011446:Prospective Studies; D012307:Risk Factors; D014777:Virus Diseases / Q000175:diagnosis; D015054:Zymosan / Q000494:pharmacology
D009895:Opsonin Proteins; D008165:Luminol; D015054:Zymosan; D000118:Acetylglucosaminidase; D010196:Pancreatic Elastase